Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISIONBLUE vs BUTRANS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
Staining of the anterior lens capsule during cataract surgery or capsulorhexis,Staining of vitreous in vitrectomy procedures
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Treatment of opioid dependence (as part of medication-assisted treatment)
0.5 m L of 0.025% solution intracameral injection (single use).
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
Approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 12 hours).
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Visionblue is not metabolized; it is cleared from the eye via aqueous humor outflow and systemic absorption is negligible.
Primarily metabolized by CYP3A4 to norbuprenorphine; also undergoes conjugation with glucuronic acid. Norbuprenorphine is active and further glucuronidated.
Primarily eliminated unchanged via renal glomerular filtration; minimal biliary excretion (<5%).
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Negligible (<5%), primarily to albumin.
96% bound primarily to albumin and alpha-1-acid glycoprotein
0.2 L/kg, reflecting confinement to extracellular fluid and minimal tissue binding.
Vd: 2-5 L/kg, indicating extensive tissue distribution
Not applicable for systemic routes; intraocular administration yields direct local effect.
Transdermal: 15-25%; buccal: 60-70%
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use with caution and consider starting at the lowest dose (5 mcg/h) with close monitoring for adverse effects.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Start at the lowest dose (5 mcg/h) and titrate cautiously; consider reducing dose by 50%. Child-Pugh Class C: Avoid use due to increased risk of toxicity.
Safety and efficacy not established in pediatric patients; no standard dosing available.
Not recommended for use in pediatric patients under 18 years of age due to lack of safety and efficacy data.
No specific adjustment; use adult dosing as indicated.
Initiate at the lowest dose (5 mcg/h) and titrate slowly with careful monitoring for respiratory depression, sedation, and falls. Consider age-related reductions in renal and hepatic function.
None
Risk of respiratory depression, addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome; risk of potentially fatal respiratory depression when used with benzodiazepines or other CNS depressants; and risk of life-threatening respiratory depression in children with accidental ingestion.
Intraocular use only; do not inject intravenously,Potential for corneal endothelial toxicity if excessive volume or prolonged contact,May cause transient increase in intraocular pressure,Hypersensitivity reactions have been reported,Use with caution in patients with compromised corneal endothelium
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; risk with benzodiazepines or other CNS depressants; severe hypotension; gastrointestinal obstruction; seizures; biliary tract disease; use in elderly and debilitated patients; hepatic impairment; renal impairment; pregnancy; lactation.
Known hypersensitivity to trypan blue or any component of the formulation,Intraocular use in patients with significant corneal endothelial compromise
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
No known food interactions. This drug is administered intraocularly and is not ingested; systemic absorption is negligible.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially increasing buprenorphine levels. No other significant food interactions documented.
No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.
First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use near term due to risk of respiratory depression. Generally, buprenorphine is considered lower risk than full agonists but still requires careful risk-benefit assessment.
Minimal systemic absorption; M/P ratio not reported. Compatible with breastfeeding but avoid direct infant eye contact.
Buprenorphine is excreted into breast milk. M/P ratio approximately 0.3 (range 0.1-0.6). Relative infant dose about 1-2% of maternal weight-adjusted dose. Monitor infant for sedation, respiratory depression, and withdrawal if breastfeeding is initiated or discontinued. Generally compatible with breastfeeding in stable patients.
No dosage adjustment needed; pharmacokinetics unchanged in pregnancy.
No routine dose adjustment recommended. However, increased clearance in pregnancy may require dose titration based on clinical response. Monitor for withdrawal symptoms as pregnancy progresses; dose may need to be increased. Postpartum, dose may need to be reduced due to restored clearance.
Vision Blue (trypan blue ophthalmic solution 0.06%) is a vital dye used as a surgical aid in cataract surgery for staining the anterior capsule during capsulorhexis. It selectively stains the anterior lens capsule due to its affinity for basement membranes, facilitating visualization in eyes with poor red reflex (e.g., white cataracts, dense brunescent cataracts). Avoid injecting into the vitreous; if encountered, perform anterior vitrectomy immediately. Use with caution in patients with pseudophakic or aphakic eyes due to risk of dye retention in the vitreous. Discard any unused solution after surgery; single-use vial only.
BUTRANS (buprenorphine transdermal system) is a Schedule III partial mu-opioid agonist used for chronic pain. Do not apply to irritated skin; rotate application sites to minimize skin reactions. Onset of analgesia is delayed (12-24 hours), so titrate with immediate-release analgesics as needed. Avoid concurrent use with full mu-opioid agonists (e.g., morphine) due to risk of precipitated withdrawal. The 5, 7.5, 10, 15, and 20 mcg/h patches are approved; 20 mcg/h is the maximum single dose. Reserve for patients tolerant to around-the-clock opioids (≥30 mg oral morphine equivalents/day). Monitor for respiratory depression (less than full agonists, but still a risk) and serotonin syndrome with other serotonergic agents.
This medication is used during eye surgery to help your surgeon see the lens capsule clearly.,It is not self-administered; it will be applied by your surgeon during the procedure.,Inform your surgeon about any allergies, especially to dyes or medications.,Report any eye pain, redness, or vision changes after surgery immediately.,You may experience temporary blue discoloration of the eye, which resolves within days.
Apply the patch to clean, dry, hairless skin on the upper arm, chest, back, or side of the chest. Remove immediately if it falls off.,Wear the patch for 7 days; replace with a new patch at the same time of day. Do not cut or damage the patch.,Avoid exposure to direct heat (heating pads, saunas, hot tubs, prolonged sun) as it increases absorption and overdose risk.,Do not drink alcohol while using Butrans; it can cause dangerous side effects.,Keep all patches away from children and pets; used patches should be folded and flushed down the toilet immediately.,Do not stop abruptly or change dose without consulting your doctor; withdrawal may occur.,Common side effects include nausea, constipation, headache, and application site redness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISIONBLUE vs BUTRANS, answered by our medical review team.
VISIONBLUE is a Ophthalmic Dye/Stain that works by Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.. BUTRANS is a Opioid Analgesic that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISIONBLUE and BUTRANS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISIONBLUE is: 0.5 m L of 0.025% solution intracameral injection (single use).. The standard adult dose of BUTRANS is: Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISIONBLUE and BUTRANS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISIONBLUE is classified as Category C. No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.. BUTRANS is classified as Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Prolonged use can cause neonatal opioid withdraw. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.